Plasma and Intrapulmonary Concentrations Study of WCK 5222
NCT03630094
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
36
Enrollment
INDUSTRY
Sponsor class
Conditions
PHA1A
Interventions
DRUG:
FEP-ZID
Sponsor
Wockhardt